Table 3.
GRADE assessment of outcome indicators
| Outcome indicators | Risk of bias | Inconsistency | Indirectness | Imprecision | Publication bias | GRADE quality |
|---|---|---|---|---|---|---|
| Febuxostat (40 mg/d) versus allopurinol (200–300 mg/d) in percentage of patients achieving serum uric acid levels 6.0 mg/dL or less | Serious | Serious | Not serious | Not serious | Undetected | ⊕⊕○○/ Low |
| Febuxostat (80 mg/d) versus allopurinol (200–300 mg/d) in percentage of patients achieving serum uric acid levels 6.0 mg/dL or less | Serious | Serious | Not serious | Not serious | Undetected | ⊕⊕○○/ Low |
| Febuxostat (40 mg/d) versus allopurinol (200–300 mg/d) in incidence of gout | Serious | Not serious | Not serious | Not serious | Undetected | ⊕⊕○/Moderate |
| Febuxostat (80 mg/d) versus allopurinol (200–300 mg/d) in incidence of gout | Serious | Serious | Not serious | Not serious | Undetected | ⊕⊕○○/ Low |
| Febuxostat (40 mg/d) versus allopurinol (200–300 mg/d) in incidence of serious adverse reactions | Serious | Not serious | Not serious | Not serious | Undetected | ⊕⊕○/Moderate |
| Febuxostat (80 mg/d) versus allopurinol (200–300 mg/d) in incidence of serious adverse reactions | Serious | Serious | Not serious | Not serious | Undetected | ⊕⊕○○/ Low |
| Febuxostat (40 mg/d) versus allopurinol (200–300 mg/d) in incidence of adverse cardiovascular reactions | Serious | Not serious | Not serious | Not serious | Undetected | ⊕⊕○/Moderate |
| Febuxostat (80 mg/d) versus allopurinol (200–300 mg/d) in incidence of adverse cardiovascular reactions | Serious | Serious | Not serious | Not serious | Undetected | ⊕⊕○○/ Low |
GRADE, Grading of Recommendations Assessment, Development, and Evaluation